Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer

Clinical Genitourinary Cancer

Volumn 14, Issue 2, 2016, Pages e233-e236

  Chedgy, Edmund C P ^a   Annala, Matti ^a,b   Beja, Kevin ^a   Warner, Evan W ^a   Gleave, Martin E ^a   Chi, Kim N ^a,c   Wyatt, Alexander W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Institute of Biosciences and Medical Technology   (Finland)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Cell free DNA; ctDNA; DNA damage repair; Precision medicine; Small cell carcinoma

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT; BRCA2 PROTEIN, HUMAN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL RECTAL EXAMINATION; DNA DAMAGE; DNA REPAIR; GENE DELETION; HUMAN; LIQUID BIOPSY; LIVER METASTASIS; MALE; MIDDLE AGED; NEUROENDOCRINE PROSTATE CANCER; PERSONALIZED MEDICINE; PROSTATE CANCER; TREATMENT RESPONSE; TUMOR BIOPSY; CARCINOMA, NEUROENDOCRINE; GENETICS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRCA2 PROTEIN; CARCINOMA, NEUROENDOCRINE; CISPLATIN; GENE DELETION; HUMANS; MALE; MIDDLE AGED; PRECISION MEDICINE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84960435339     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2015.12.023     Document Type: Article

References (17)

1. H.T. Wang, Y.H. Yao, B.G. Li, Y. Tang, J.W. Chang, and J. Zhang Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis J Clin Oncol 32 2014 3383 3390
2. H. Beltran, S.T. Tagawa, K. Park, and et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer J Clin Oncol 30 2012 e386 e389
3. V. Parimi, R. Goyal, K. Poropatich, and X.J. Yang Neuroendocrine differentiation of prostate cancer: a review Am J Clin Exp Urol 2 2014 273 285
4. R. Nadal, M. Schweizer, O.N. Kryvenko, J.I. Epstein, and M.A. Eisenberger Small cell carcinoma of the prostate Nat Rev Urol 11 2014 213 219
5. P. Sargos, L. Ferretti, M. Gross-Goupil, and et al. Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review Prostate Cancer Prostatic Dis 17 2014 220 226
6. C.C. Guo, J.Y. Dancer, Y. Wang, and et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate Hum Pathol 42 2011 11 17
7. T.L. Lotan, N.S. Gupta, W. Wang, and et al. ERG gene rearrangements are common in prostatic small cell carcinomas Mod Pathol 24 2011 820 828
8. S.R. Williamson, S. Zhang, J.L. Yao, and et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin Mod Pathol 24 2011 1120 1127
9. S. Akamatsu, A.W. Wyatt, D. Lin, and et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer Cell Rep 12 2015 922 936
10. A.M. Aparicio, A.L. Harzstark, P.G. Corn, and et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer Clin Cancer Res 19 2013 3621 3630
11. A.A. Azad, S.V. Volik, A.W. Wyatt, and et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer Clin Cancer Res 21 2015 2315 2324
12. D. Vesprini, S.A. Narod, J. Trachtenberg, and et al. The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers Can Urol Assoc J 5 2011 E31 E35
13. Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet, Published online June 11, 2015; http://dx.doi.org/10.1016/S0140-6736(14)61947-4.
14. D.J. Gallagher, A.M. Cronin, M.I. Milowsky, and et al. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer BJU Int 109 2012 713 719
15. J. Mateo, S. Carreira, S. Sandhu, and et al. DNA-repair defects and olaparib in metastatic prostate cancer N Engl J Med 373 2015 1697 1708
16. A. Romanel, D.G. Tandefelt, V. Conteduca, and et al. Plasma AR and abiraterone-resistant prostate cancer Sci Transl Med 7 2015 312re310
17. D. Robinson, E.M. Van Allen, Y.M. Wu, and et al. Integrative clinical genomics of advanced prostate cancer Cell 161 2015 1215 1228